2026 Q2 - tulosraportti
75 päivää sitten
‧1 t 38 min
10,32 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 84 | - | - | ||
| 36 | - | - | ||
| 130 | - | - | ||
| 70 | - | - | ||
| 4 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 30.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 10.2. | ||
2025 Q3 - tulosraportti 6.11.2025 | ||
2025 Q2 - tulosraportti 29.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 päivä sittenDull development right now what is required to break it
The share price should be above 2000kr at the latest within 6 months. If a shift from tech to defensive stocks like pharma also happens, it can go even faster.
·1 päivä sittenThe long-term scenario (daily view) still looks quite good. The price has been down and turned just above the trendline and the price is in the cloud and has a green cloud 26 days ahead. The price is also between two MA lines (20 and 50), where the 50 line provides support and the 20 line resistance. The ChikouSpan line is located within the price bars, which speaks for consolidation. SenkouSpanB has support at 1583kr (future) and if the price now stays above 1556kr, then we see the double bottom a halfway formation and a latest first correction wave (b) abc movement in Elliott wave theory. The daily chart view looks good. Neutral volume balance. Higher pivot lows in SMACD since early May. A large gap is waiting to be closed between 1730 and 1880kr (though that will probably take a while) and a small one between 1630kr and 1600kr. So I definitely see a positive development looking forward to Christmas! We will see how it develops...
Do you think technical analysis works just as well in a stock like Astra, where over 90% of the trading seems to come from various algo-traders playing against each other. It must be just a drop in the volume that consists of a person/company actually investing in the company. Maybe it looks like that on the rest of omx30 too i guess :)
·1 päivä sittenUSA opens in 10min, so now we get to see if they let Astra run, or not today... ;-)
I think management needs to address this soon. Everyone can see it's manipulation
·2 päivää sittenThe AI boom will transform the development of new drugs ASTRA ZENECA: HAS WHAT IT TAKES FOR GROWTH BEYOND 2030 ACCORDING TO CEOAI will drastically shorten the time, lower costs, and increase accuracy in the development of new drugs. Key changes • Shorter development time: The process from initial idea to clinical trials can go from previously 4–5 years down to under 12 months. The total time from research to finished medicine (which often takes over ten years) is shortened in the early phases. • Better molecule selection: Algorithms can weigh in and analyze thousands or millions of molecules directly in the initial selection, making it possible to predict early on which candidates actually work and have appropriate toxicity. • Robotic laboratories: Researchers combine AI with robotics and methods like "cell painting" to conduct tens of thousands of experiments a week in parallel, building large datasets to train the AI models. Read more about this at Uppsala University. • Lower costs: Traditionally, it has been required to develop and test around 10,000 candidates at enormous costs (on average over 20 billion SEK for approved preparations according to older estimates). AI reduces the need for blind trial-and-error tests. • Reduced animal testing: Better simulations and cell analyses via AI and automation make it possible to replace or reduce the number of animal tests. • New administration forms: AI helps researchers understand how drugs are absorbed in the body, which in the long run can transform certain injections into regular tablets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
75 päivää sitten
‧1 t 38 min
10,32 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenDull development right now what is required to break itThe share price should be above 2000kr at the latest within 6 months. If a shift from tech to defensive stocks like pharma also happens, it can go even faster.
- ·1 päivä sittenThe long-term scenario (daily view) still looks quite good. The price has been down and turned just above the trendline and the price is in the cloud and has a green cloud 26 days ahead. The price is also between two MA lines (20 and 50), where the 50 line provides support and the 20 line resistance. The ChikouSpan line is located within the price bars, which speaks for consolidation. SenkouSpanB has support at 1583kr (future) and if the price now stays above 1556kr, then we see the double bottom a halfway formation and a latest first correction wave (b) abc movement in Elliott wave theory. The daily chart view looks good. Neutral volume balance. Higher pivot lows in SMACD since early May. A large gap is waiting to be closed between 1730 and 1880kr (though that will probably take a while) and a small one between 1630kr and 1600kr. So I definitely see a positive development looking forward to Christmas! We will see how it develops...Do you think technical analysis works just as well in a stock like Astra, where over 90% of the trading seems to come from various algo-traders playing against each other. It must be just a drop in the volume that consists of a person/company actually investing in the company. Maybe it looks like that on the rest of omx30 too i guess :)
- ·1 päivä sittenUSA opens in 10min, so now we get to see if they let Astra run, or not today... ;-)I think management needs to address this soon. Everyone can see it's manipulation
- ·2 päivää sittenThe AI boom will transform the development of new drugs ASTRA ZENECA: HAS WHAT IT TAKES FOR GROWTH BEYOND 2030 ACCORDING TO CEOAI will drastically shorten the time, lower costs, and increase accuracy in the development of new drugs. Key changes • Shorter development time: The process from initial idea to clinical trials can go from previously 4–5 years down to under 12 months. The total time from research to finished medicine (which often takes over ten years) is shortened in the early phases. • Better molecule selection: Algorithms can weigh in and analyze thousands or millions of molecules directly in the initial selection, making it possible to predict early on which candidates actually work and have appropriate toxicity. • Robotic laboratories: Researchers combine AI with robotics and methods like "cell painting" to conduct tens of thousands of experiments a week in parallel, building large datasets to train the AI models. Read more about this at Uppsala University. • Lower costs: Traditionally, it has been required to develop and test around 10,000 candidates at enormous costs (on average over 20 billion SEK for approved preparations according to older estimates). AI reduces the need for blind trial-and-error tests. • Reduced animal testing: Better simulations and cell analyses via AI and automation make it possible to replace or reduce the number of animal tests. • New administration forms: AI helps researchers understand how drugs are absorbed in the body, which in the long run can transform certain injections into regular tablets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 84 | - | - | ||
| 36 | - | - | ||
| 130 | - | - | ||
| 70 | - | - | ||
| 4 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 30.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 10.2. | ||
2025 Q3 - tulosraportti 6.11.2025 | ||
2025 Q2 - tulosraportti 29.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
75 päivää sitten
‧1 t 38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 30.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 27.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 10.2. | ||
2025 Q3 - tulosraportti 6.11.2025 | ||
2025 Q2 - tulosraportti 29.7.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
10,32 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenDull development right now what is required to break itThe share price should be above 2000kr at the latest within 6 months. If a shift from tech to defensive stocks like pharma also happens, it can go even faster.
- ·1 päivä sittenThe long-term scenario (daily view) still looks quite good. The price has been down and turned just above the trendline and the price is in the cloud and has a green cloud 26 days ahead. The price is also between two MA lines (20 and 50), where the 50 line provides support and the 20 line resistance. The ChikouSpan line is located within the price bars, which speaks for consolidation. SenkouSpanB has support at 1583kr (future) and if the price now stays above 1556kr, then we see the double bottom a halfway formation and a latest first correction wave (b) abc movement in Elliott wave theory. The daily chart view looks good. Neutral volume balance. Higher pivot lows in SMACD since early May. A large gap is waiting to be closed between 1730 and 1880kr (though that will probably take a while) and a small one between 1630kr and 1600kr. So I definitely see a positive development looking forward to Christmas! We will see how it develops...Do you think technical analysis works just as well in a stock like Astra, where over 90% of the trading seems to come from various algo-traders playing against each other. It must be just a drop in the volume that consists of a person/company actually investing in the company. Maybe it looks like that on the rest of omx30 too i guess :)
- ·1 päivä sittenUSA opens in 10min, so now we get to see if they let Astra run, or not today... ;-)I think management needs to address this soon. Everyone can see it's manipulation
- ·2 päivää sittenThe AI boom will transform the development of new drugs ASTRA ZENECA: HAS WHAT IT TAKES FOR GROWTH BEYOND 2030 ACCORDING TO CEOAI will drastically shorten the time, lower costs, and increase accuracy in the development of new drugs. Key changes • Shorter development time: The process from initial idea to clinical trials can go from previously 4–5 years down to under 12 months. The total time from research to finished medicine (which often takes over ten years) is shortened in the early phases. • Better molecule selection: Algorithms can weigh in and analyze thousands or millions of molecules directly in the initial selection, making it possible to predict early on which candidates actually work and have appropriate toxicity. • Robotic laboratories: Researchers combine AI with robotics and methods like "cell painting" to conduct tens of thousands of experiments a week in parallel, building large datasets to train the AI models. Read more about this at Uppsala University. • Lower costs: Traditionally, it has been required to develop and test around 10,000 candidates at enormous costs (on average over 20 billion SEK for approved preparations according to older estimates). AI reduces the need for blind trial-and-error tests. • Reduced animal testing: Better simulations and cell analyses via AI and automation make it possible to replace or reduce the number of animal tests. • New administration forms: AI helps researchers understand how drugs are absorbed in the body, which in the long run can transform certain injections into regular tablets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 84 | - | - | ||
| 36 | - | - | ||
| 130 | - | - | ||
| 70 | - | - | ||
| 4 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt